Preclinical Evaluation of the Reversible Monoacylglycerol Lipase PET Tracer (R)‐[¹¹C]YH132: Application in Drug Development and Neurodegenerative Diseases

Abstract

Monoacylglycerol lipase (MAGL) plays a crucial role in the degradation of 2‐arachidonoylglycerol (2‐AG), one of the major endocannabinoids in the brain. Inhibiting MAGL could lead to increased levels of 2‐AG, which showed beneficial effects on pain management, anxiety, inflammation, and neuroprotection. In the current study, we report the characterization of an enantiomerically pure (R)‐[11C]YH132 as a novel MAGL PET tracer. It demonstrates an improved pharmacokinetic profile compared to its racemate. High in vitro MAGL specificity of (R)‐[11C]YH132 was confirmed by autoradiography studies using mouse and rat brain sections. In vivo, (R)‐[11C]YH132 displayed a high brain penetration, and high specificity and selectivity toward MAGL by dynamic PET imaging using MAGL knockout and wild‐type mice. Pretreatment with a MAGL drug candidate revealed a dose‐dependent reduction of (R)‐[11C]YH132 accumulation in WT mouse brains. This result validates its utility as a PET probe to assist drug development. Moreover, its potential application in neurodegenerative diseases was explored by in vitro autoradiography using brain sections from animal models of Alzheimer's disease and Parkinson's disease.